Verspohl E J, Johannwille B, Kaiserling-Buddemeier I, Schlüter H, Hagemann J
Department of Pharmacology, Institute of Pharmaceutical Chemistry, University of Münster, Germany.
J Pharm Pharmacol. 1999 Oct;51(10):1175-81. doi: 10.1211/0022357991776714.
The role of diadenosine polyphosphates (ApnA, where "A" denotes "adenosine" and "n" denotes the number of phosphate groups "p") as vasoconstrictors of smooth-muscle cells and as blood-pressure regulating and insulin-releasing compounds has been described. It was the aim of this study to investigate whether specific receptors for these compounds, mediating the above mentioned effects, occur in cultured vascular smooth-muscle cells (VSMC) and in endothelium cells, and whether these compounds are degraded during incubation. Saturable binding sites for diadenosine polyphosphate [3H]Ap4A with an extremely quick saturation equilibrium, even at low temperature (4 degrees C), are present in vascular smooth-muscle cells. Diadenosine polyphosphates at micromolar concentrations displaced [3H]Ap4A from binding sites; the ranking order was Ap4A > Ap3A > Ap5A approximately Ap6A. Compounds interacting with purinergic P2X receptors such as suramin, alpha,beta-methylene ATP and pyridoxalphosphate-6-azophenyl-2',4'-disulphonic acid (PPADS), albeit at high concentrations, displaced [3H]Ap4A from its binding sites. Surprisingly, at low concentrations the compounds tested increased the binding of [3H]Ap4A, which might imply the occurrence of positive receptor cooperativity or inhibition of [3H]Ap4A degradation. By use of thin-layer chromatography it was observed that [3H]Ap4A was quickly degraded (half-life approx. 12 min) in the extracellular medium to (mainly) adenosine and inosine. [3H]Ap4A and its degradation products were quickly taken up by the cells. Degradation can be inhibited by Ap6A, alpha,beta-methylene ATP or PPADS. Rather similar degradation and uptake results were also obtained when endothelium cells were used. These data indicate that specific binding sites for [3H]Ap4A are present in vascular smooth-muscle cells and that diadenosine polyphosphates at physiological concentrations displace binding. The receptors involved might be distinct diadenosine polyphosphate receptors, although the involvement of others, such as P2X receptors, is also possible. Ap4A is quickly degraded in the extracellular space and compounds that inhibit degradation result in an increase in [3H]Ap4A binding. It should be remembered that when diadenosine polyphos-phates are being investigated in physiological and pathophysiological studies of their impact on smooth-muscle cell proliferation and on vasoconstriction (blood-pressure regulation), results obtained from long-term incubations might be critical.
二腺苷多磷酸(ApnA,其中“A”表示“腺苷”,“n”表示磷酸基团“p”的数量)作为平滑肌细胞的血管收缩剂以及作为血压调节和胰岛素释放化合物的作用已被描述。本研究的目的是调查介导上述作用的这些化合物的特异性受体是否存在于培养的血管平滑肌细胞(VSMC)和内皮细胞中,以及这些化合物在孵育过程中是否会降解。血管平滑肌细胞中存在二腺苷多磷酸[3H]Ap4A的可饱和结合位点,即使在低温(4℃)下,其饱和平衡也极快。微摩尔浓度的二腺苷多磷酸可将[3H]Ap4A从结合位点上置换下来;置换顺序为Ap4A > Ap3A > Ap5A ≈ Ap6A。与嘌呤能P2X受体相互作用的化合物,如苏拉明、α,β-亚甲基ATP和磷酸吡哆醛-6-偶氮苯基-2',4'-二磺酸(PPADS),尽管浓度很高,但也能将[3H]Ap4A从其结合位点上置换下来。令人惊讶的是,在低浓度下,所测试的化合物会增加[3H]Ap4A的结合,这可能意味着存在正性受体协同作用或对[3H]Ap4A降解的抑制。通过薄层色谱法观察到,[3H]Ap4A在细胞外培养基中迅速降解(半衰期约12分钟),主要降解为腺苷和肌苷。[3H]Ap4A及其降解产物迅速被细胞摄取。Ap6A、α,β-亚甲基ATP或PPADS可抑制降解。使用内皮细胞时也获得了相当类似的降解和摄取结果。这些数据表明,血管平滑肌细胞中存在[3H]Ap4A的特异性结合位点,生理浓度的二腺苷多磷酸可置换结合。所涉及的受体可能是不同的二腺苷多磷酸受体,尽管其他受体如P2X受体也有可能参与。Ap4A在细胞外空间迅速降解,抑制降解的化合物会导致[3H]Ap4A结合增加。应该记住,在对二腺苷多磷酸对平滑肌细胞增殖和血管收缩(血压调节)的生理和病理生理影响进行研究时,长期孵育获得的结果可能至关重要。